SGMT241220P7500
- 2.50
- 0.000.00%
Sagimet Biosciences Newsroom
Sagimet Biosciences Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$141m
Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
Institutional Investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) See US$36m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Sagimet Biosciences Analyst Ratings
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32
Sagimet Biosciences Advances MASH Treatment With Denifanstat
Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating
Sagimet Biosciences | 8-K: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Q3 EPS (45c) Vs (35c) Last Year
Sagimet Biosciences | 10-Q: Q3 2024 Earnings Report
Express News | Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Express News | Sagimet Biosciences Q3 Net Income USD -14.619 Million
Sagimet Biosciences 3Q Loss/Shr 45c >SGMT
Press Release: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
UBS Initiates Sagimet Biosciences(SGMT.US) With Buy Rating, Announces Target Price $12
Sagimet Biosciences: Promising Drug Denifanstat and Market Potential Drive Buy Rating
Sagimet Biosciences Initiated With a Buy at UBS
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference